Waldemar Radziszewski

4PUBLICATIONS
12CO-AUTHORS
Pharmaceutical delivery technologiesApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Autoimmunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Apr 09, 2026
Comparative Study Assessing Multiple Switches Between Biosimilar ABP 501 (adalimumab-atto) and Adalimumab Reference Product in Patients with Plaque Psoriasis.

Paul S Yamauchi, Vincent Chow, Daniel T Mytych

|Mar 20, 2026
Pharmacokinetic, Safety, and Immunogenicity Similarity of High- and Low-Concentration Formulations of Adalimumab Biosimilar ABP 501, Adalimumab-Atto.

Vincent Chow, Muhan Zhou, Daniel T Mytych

|Mar 11, 2025
Real-World Experience with an Adalimumab Biosimilar (ABP 501) in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis and Psoriasis in Europe: Results from the Adelphi Disease Specific Programme.

Ran Jin, James M Haughton, Emily J Goddard

|Nov 13, 2023
Real-World Experience of Adalimumab Biosimilar (ABP 501) Use in Patients with Inflammatory Bowel Disease in Europe.

Ran Jin, Chidozie Nduka, Delphine Courmier

Pageof 1

Frequent Collaborators

2 joint publications

Ran Jin

2 joint publications

Delphine Courmier

2 joint publications

Rachael Meadows

2 joint publications

James Piercy